Skip to content

Early biological markers of renal dysfunction in elderly and early identification protocol for a population with comorbidities

Early biological markers of renal dysfunction in elderly and early identification protocol for a population with comorbidities

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065733
Enrollment
Unknown
Registered
2022-11-14
Start date
2022-11-19
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout kidney injury

Interventions

Gold Standard:Gout kidney injury is diagnosed when the following conditions are met: 1. History of gout or high uric acid
2. Except for renal insufficiency caused by other reasons.
Index test:Blood LAMP2, urine LAMP2, kidney dual-energy CT, renal tubule injury marker protein, blood uric acid.

Sponsors

Huadong Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. All gout diagnoses must meet the new gout classification criteria jointly revised by the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) in 2015; Hyperuricemia was diagnosed by fasting blood uric acid level >420 µmol/L twice on different days under normal purine diet; 3. Subjects must voluntarily participate in the study and comply with the study regulations, understand and comply with the follow-up plan, and voluntarily sign a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with typical uric acid nephrolithiasis; 2. Drugs that affect uric acid excretion should be taken within 2 weeks before the visit, such as urico-lowering drugs (including benzbromarone, allopurinol, febuxostat), aspirin, diuretics, cyclosporine, sodium bicarbonate, levodopa, antituberculosis drugs, calcium channel blockers, ACEI, ARB, ß-blockers, a-glucosidase inhibitors, insulin sensitizers, DPP-4 inhibitors, SGLT-2 inhibitors, metformin, exenatide, fenofibrate, atorvastatin; Taking glucocorticoid, immunosuppressant and other drugs affecting immunity in the past 3 months; Antibiotics, probiotics and other drugs that affect the body's flora; A history of medications that may cause gum swelling: Phenytoin sodium; Cyclosporine; 3. Patients with hyperuricemia caused by secondary factors, such as leukemia, myeloma, renal failure, polycystic kidney, some endocrine diseases, metabolic acidosis, and high uric acid caused by certain drugs, such as diuretics, aspirin, and antituberculous drugs; Hereditary hyperuricemia was excluded; 4. Oral mucosa lesions with clinical significance, such as traumatic ulcers, bacterial stomatitis, and keratitis; 5. All patients in the study had diets high in purine, high protein, fructose, sodium, potassium and alcohol 5 days before sample retention, so as not to affect test results; 6. Patients with abnormal stool morphology, such as diarrhea, dry stool, etc.; 7. Severe abnormal cardiopulmonary and liver function; 8. Patients with renal tubulointerstitial diseases, peritoneal dialysis, hemodialysis and kidney transplantation; 9. High purine and fructose-rich diet and alcohol consumption within 3 days prior to the examination.

Design outcomes

Primary

MeasureTime frame
Blood exosome lysosome associated membrane protein 2;Urinary exosome lysosome associated membrane protein 2;Renal dual energy CT;

Secondary

MeasureTime frame
Urinary trace protein;Blood uric acid concentration;

Countries

China

Contacts

Public ContactXiao Jing

Huadong Hospital Affiliated to Fudan University

carolshaw7@126.com+86 13817100256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026